Curie Oncology, one of south-east Asia’s fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials.

The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore’s public healthcare system.

Curie runs numerous clinical trials across Singapore and Malaysia. As the group expands its research footprint, the volume of data required to identify eligible patients has increased significantly.

Digitalisation in healthcare has generated large volumes of data with valuable clinical insights. This information ranges from structured datasets such as lab results to unstructured content such as free-text notes created inside and outside clinical environments. Yet over 80% of health data are unstructured, making it difficult for research teams to process efficiently or consistently. These limitations create barriers for researchers who need reliable, analysis-ready information.

Through the partnership, Curie is using Oncoshot’s AI tools to structure and analyse clinical data, enabling its oncologists and research teams to identify eligible patients sooner and offer access to ongoing trials more efficiently.

“Oncoshot helped us restructure our rich clinical and genomic data,” said Toh Chee Keong, head of research at Curie Oncology. “We can now use natural language to query this information, enabling us to match patients to innovative therapies, improve patient outcomes and perform cost-benefit analysis.”

Oncoshot’s platform functions as a secure, behind-the-scenes engine that converts unstructured oncology documents into research-ready datasets. During Curie’s rollout, the AI system extracted and de-identified data with over 95% accuracy, even across varied source systems, and allowed research coordinators to spend more time on patient-facing and trial-critical tasks, instead of repetitive data processing.

Oncoshot’s role is to support not replace Curie’s clinical research processes. The AI system helps teams screen faster, run feasibility checks more consistently and scale their research programmes without requiring proportional increases in labour.

“Our focus is to enable clinicians and research staff to do what they do best: care for patients and run high-quality clinical studies,” said Huren Sivaraj, CEO of Oncoshot. “AI simply removes the manual bottlenecks that make oncology research and access to innovative trials so resource intensive.”

Curie is among the first private oncology networks in Asia to deploy Oncoshot’s AI platform, extending the company’s work with earlier public-facing collaborations across Singapore’s cancer research ecosystem.

This includes earlier collaborations such as a 2022 project with Icon Cancer Centre and Roche to digitise genomic data, a workflow that has since been fully automated, as well as deployments with Tan Tock Seng Hospital and the National Cancer Centre Singapore.

Together, these implementations illustrate how AI can support public and private cancer institutions in processing unstructured oncology data securely and efficiently. Oncoshot’s federated architecture ensures raw patient data remain within each institution’s environment, while maintaining compliance with HIPAA, GDPR and Singapore PDPC regulations.

Curie Oncology (curieoncology.com.sg) is a multi-site regional oncology group operating across Singapore, Malaysia and the Philippines, with active collaborations in Indonesia and Vietnam.

Oncoshot (www.oncoshot.com) is an oncology-focused AI company that helps hospitals and cancer centres transform unstructured clinical data into secure, analysis-ready datasets.